The effects of Ginger in treatment COVID-19

INTERVENTION: Intervention 1: Intervention group: The standard treatment regimen for COVID‐19 along with a Ginger‐based herbal medicine (Vomigone 500 mg tablets, registration number: 9406633051781240, Dineh Iran Pharmaceutical Company) at a dose of 1000 mg three times a day for a period of 14 days. Intervention 2: Control group: The standard treatment for COVID‐19 based on the Ministry of Health's protocol including hydroxychloroquine sulfate (Amin Pharmaceutical company, Isfahan) at a dose of 200 mg twice a day for a period of 14 days, along with a Vomigone‐liked placebo tablets (Dineh Iran Pharmaceutical Company) at a dose of two tablets three times a day for a period of 14 days. CONDITION: COVID‐19 disease. ; COVID‐19, virus not identified U07.2 PRIMARY OUTCOME: Body temperature. Timepoint: Before intervention and daily during the study. Method of measurement: Thermometer. Oxygen saturation. Timepoint: Before intervention and daily during the study. Method of measurement: Pulse oximeter. Respiratory rate. Timepoint: Before intervention and daily during the study. Method of measurement: Respiratory Count. SECONDARY OUTCOME: C‐reactive protein. Timepoint: Before intervention and days 7 and 14 after the intervention. Method of measurement: C‐RP kit. Incidence of serious adverse events. Timepoint: Before intervention and daily during the study. Method of measurement: Questionnaire. Lymphocytopenia. Timepoint: Before intervention and days 7 and 14 after the intervention. Method of measurement: Cell count. INCLUSION CRITERIA: Age =18 years Positive polymerase chain reaction (PCR) test for COVID‐19 or/and lung involvement in imaging Primary clinical symptoms Hospitalized Signing informed consent and willingness of study participant to accept randomization to any assigned treatment arm